【摘要】 目的:探讨外伤性脑内出血患者血浆ET-1和CGRP变化以及依达拉奉治疗对血浆ET-1和CGRP的影响。方法:80例外伤性脑内出血患者随机分为依达拉奉组与常规治疗组,另取30例健康人作为对照组。用放射免疫分析测定外伤性脑内出血患者依达拉奉治疗前后血浆ET-1、CGRP含量。结果:依达拉奉组和常规治疗组治疗前血浆ET-1显著增高,治疗后明显下降,治疗后血浆ET-1降低常规治疗组明显少于依达拉奉组(P<0.01);依达拉奉组和常规治疗组治疗前血浆CGRP显著降低,治疗后明显升高,治疗后血浆CGRP增加,依达拉奉组明显高于常规治疗组(P<0.01)。结论:外伤性脑内出血患者血浆ET-1水平显著升高,CGRP水平显著降低;早期应用依达拉奉可显著降低ET-1和提高CGRP水平,初步研究显示,依达拉奉具有脑保护作用。伤后早期应用依达拉奉可改善病人预后。更多还原

【Abstract】 Objective To investigate the effect of edaravone treatment on plasma ET-1 and CGRP levels changes in patients with traumatic intracerebral hemorrhage.Methods Plasma ET-1 and CGRP levels were measured with RIA in 40 patients with traumatic intracerebral hemorrhage both before and after treatment with 60mg of edaravone i.v.q.d.for 5 days,40 patients both before and after treatment with conventional treatment only(without edaravone) and 30 controls(once only).Results The plasma ET-1 levels were significantly increased in all the patients at admission than those in controls.After treatment,the levels in all the patients dropped significantly,but the levels were significantly lower in edaravone-treated patients than those in non-edaravone-treated patients(P<0.01).The reverse was true for plasma CGRP levels.Conclusion Edaravone treatment could correct the abnormal plasma ET-1 and CGRP levels in patients with traumatic intracerebral hemorrhage and might be beneficial to recovery.更多还原